Free Trial
NASDAQ:LFCR

Lifecore Biomedical (LFCR) Stock Price, News & Analysis

Lifecore Biomedical logo
$8.19 -0.03 (-0.36%)
As of 07/8/2025 04:00 PM Eastern

About Lifecore Biomedical Stock (NASDAQ:LFCR)

Key Stats

Today's Range
$8.11
$8.30
50-Day Range
$6.45
$8.34
52-Week Range
$3.68
$8.63
Volume
131,916 shs
Average Volume
228,366 shs
Market Capitalization
$303.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00
Consensus Rating
Moderate Buy

Company Overview

Lifecore Biomedical Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
20th Percentile Overall Score

LFCR MarketRank™: 

Lifecore Biomedical scored higher than 20% of companies evaluated by MarketBeat, and ranked 844th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Lifecore Biomedical has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Lifecore Biomedical has only been the subject of 1 research reports in the past 90 days.

  • Read more about Lifecore Biomedical's stock forecast and price target.
  • Earnings Growth

    Earnings for Lifecore Biomedical are expected to grow in the coming year, from ($0.91) to ($0.60) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Lifecore Biomedical is -5.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Lifecore Biomedical is -5.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Lifecore Biomedical has a P/B Ratio of 22.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Lifecore Biomedical's valuation and earnings.
  • Percentage of Shares Shorted

    7.04% of the float of Lifecore Biomedical has been sold short.
  • Short Interest Ratio / Days to Cover

    Lifecore Biomedical has a short interest ratio ("days to cover") of 8.8.
  • Change versus previous month

    Short interest in Lifecore Biomedical has recently decreased by 0.86%, indicating that investor sentiment is improving.
  • Dividend Yield

    Lifecore Biomedical does not currently pay a dividend.

  • Dividend Growth

    Lifecore Biomedical does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.04% of the float of Lifecore Biomedical has been sold short.
  • Short Interest Ratio / Days to Cover

    Lifecore Biomedical has a short interest ratio ("days to cover") of 8.8.
  • Change versus previous month

    Short interest in Lifecore Biomedical has recently decreased by 0.86%, indicating that investor sentiment is improving.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Lifecore Biomedical this week, compared to 5 articles on an average week.
  • Search Interest

    1 people have searched for LFCR on MarketBeat in the last 30 days.
  • MarketBeat Follows

    1 people have added Lifecore Biomedical to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Lifecore Biomedical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,824,031.00 in company stock.

  • Percentage Held by Insiders

    32.20% of the stock of Lifecore Biomedical is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    83.36% of the stock of Lifecore Biomedical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Lifecore Biomedical's insider trading history.
Receive LFCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lifecore Biomedical and its competitors with MarketBeat's FREE daily newsletter.

LFCR Stock News Headlines

Lifecore Biomedical Insider Ups Holding During Year
Presidential Bombshell: $150T Resource to Be Released as soon as this Summer?
Something extraordinary is happening in Washington. For the first time in over a century, a sitting President could release a national treasure that's been tied up in red tape, for generations. I'm talking about a $150 trillion American asset that's scattered across all 50 states. While the mainstream media focuses on political theater, this story is quietly developing behind closed doors.
See More Headlines

LFCR Stock Analysis - Frequently Asked Questions

Lifecore Biomedical's stock was trading at $7.43 at the beginning of 2025. Since then, LFCR stock has increased by 10.2% and is now trading at $8.19.

Lifecore Biomedical, Inc. (NASDAQ:LFCR) posted its quarterly earnings results on Thursday, April, 3rd. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.14) by $0.05. The company had revenue of $35.15 million for the quarter, compared to analyst estimates of $33.23 million. Lifecore Biomedical had a negative trailing twelve-month return on equity of 551.09% and a negative net margin of 35.90%.
Read the conference call transcript
.

Shares of LFCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Lifecore Biomedical investors own include JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX) and Visa (V).

Company Calendar

Last Earnings
4/03/2025
Today
7/08/2025
Next Earnings (Estimated)
8/15/2025
Fiscal Year End
5/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:LFCR
CIK
1005286
Employees
690
Year Founded
N/A

Price Target and Rating

High Price Target
$10.00
Low Price Target
$6.00
Potential Upside/Downside
-2.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$12.01 million
Pretax Margin
-34.31%

Debt

Sales & Book Value

Annual Sales
$128.26 million
Price / Cash Flow
N/A
Book Value
$0.37 per share
Price / Book
22.14

Miscellaneous

Free Float
25,103,000
Market Cap
$303.28 million
Optionable
Optionable
Beta
0.71
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:LFCR) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners